Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: GH stock price vs SUPN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SUPN's multiple
Needs SUPN P/S.
Implied fair value · at GH's multiple
Needs GH P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GH FY 2025 (ended Dec 31, 2025) · SUPN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
GUARDANT HEALTH, INC. · implied price per share
Bear
-$16.84
Base
-$19.81
Bull
-$22.78
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Bear
$11.78
Base
$13.86
Bull
$15.94
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-15.14x
0.02x
Net debt / EBITDA
Leverage against operating earnings
-0.70x
-6.69x
Cash and equivalents
Liquid reserves on the balance sheet
$1.25B
$496.66M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
GH vs NEO
Fulgent Genetics, Inc.
GH vs FLGT
EXACT SCIENCES CORP
GH vs EXAS
Natera, Inc.
GH vs NTRA
Jazz Pharmaceuticals plc
GH vs JAZZ
INCYTE CORP
GH vs INCY
ANI PHARMACEUTICALS INC
GH vs ANIP
Vanda Pharmaceuticals Inc.
GH vs VNDA
Harmony Biosciences Holdings, Inc.
GH vs HRMY
$1.50B
$23.23M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
